EPS for Simulations Plus, Inc. (SLP) Expected At $0.11

March 9, 2018 - By Hazel Jackson

 EPS for Simulations Plus, Inc. (SLP) Expected At $0.11
Investors sentiment increased to 2.06 in 2017 Q3. Its up 0.54, from 1.52 in 2017Q2. It increased, as 1 investors sold Simulations Plus, Inc. shares while 17 reduced holdings. 16 funds opened positions while 21 raised stakes. 5.43 million shares or 5.64% more from 5.14 million shares in 2017Q2 were reported.
Connors Investor Serv holds 0.07% or 31,957 shares in its portfolio. Macquarie Gp Limited holds 0% or 20,330 shares in its portfolio. Stanley holds 0.32% or 77,364 shares in its portfolio. Deutsche Commercial Bank Ag holds 0% or 19,301 shares in its portfolio. Tower Research Cap Ltd Liability (Trc) invested 0% in Simulations Plus, Inc. (NASDAQ:SLP). Rice Hall James Assocs invested in 0.06% or 83,850 shares. Legal & General Group Public Limited Co reported 0% in Simulations Plus, Inc. (NASDAQ:SLP). Wells Fargo Mn has 0% invested in Simulations Plus, Inc. (NASDAQ:SLP) for 5,097 shares. Skylands Capital Limited Liability Company invested in 0.25% or 122,950 shares. Granite Invest Partners Limited Liability has invested 0.14% of its portfolio in Simulations Plus, Inc. (NASDAQ:SLP). Bancorp Of Ny Mellon reported 31,181 shares stake. Spark Investment Mgmt Ltd Liability Corporation holds 19,300 shares or 0.02% of its portfolio. Prelude Mgmt Lc has 3,400 shares. Blair William & Communication Il has invested 0% in Simulations Plus, Inc. (NASDAQ:SLP). Denali Advsr has invested 0% in Simulations Plus, Inc. (NASDAQ:SLP).

Since September 27, 2017, it had 0 insider buys, and 3 selling transactions for $887,166 activity.

Analysts expect Simulations Plus, Inc. (NASDAQ:SLP) to report $0.11 EPS on April, 9.They anticipate $0.04 EPS change or 57.14 % from last quarter’s $0.07 EPS. SLP’s profit would be $1.90 million giving it 36.36 P/E if the $0.11 EPS is correct. After having $0.10 EPS previously, Simulations Plus, Inc.’s analysts see 10.00 % EPS growth. The stock decreased 2.44% or $0.4 during the last trading session, reaching $16. About 86,515 shares traded or 59.47% up from the average. Simulations Plus, Inc. (NASDAQ:SLP) has risen 48.65% since March 9, 2017 and is uptrending. It has outperformed by 31.95% the S&P500.

Simulations Plus, Inc. develops and sells drug discovery and development software for mechanistic modeling and simulation. The company has market cap of $276.68 million. The firm offers GastroPlus, which simulates the absorption, pharmacokinetics , and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments. It has a 45.71 P/E ratio. It also provides PKPlus, a standalone program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for NCA and compartmental PK modelling; ADMET Predictor, a chemistry computer program, which takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher that integrates with MedChem Studio and ADMET Predictor.

More notable recent Simulations Plus, Inc. (NASDAQ:SLP) news were published by: Businesswire.com which released: “Simulations Plus Launches Version 2.0 of PKPlusâ„¢” on February 01, 2018, also Businesswire.com with their article: “DILIsym Services Inc., a Simulations Plus Company, Releases DILIsym® Version 7A” published on January 11, 2018, Businesswire.com published: “Simulations Plus Releases MembranePlusâ„¢ Version 2” on August 23, 2017. More interesting news about Simulations Plus, Inc. (NASDAQ:SLP) were released by: Businesswire.com and their article: “Simulations Plus Announces Senior Management Changes” published on August 31, 2017 as well as Nasdaq.com‘s news article titled: “Simulations Plus, Inc. (SLP) Ex-Dividend Date Scheduled for November 10, 2017” with publication date: November 09, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.